A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors
To assess the safety and tolerability of TTX-080
- IRB Number: 12189
- Research Study Identifier: TX11413
- Principal Investigator: Greg Durm, MD
Recruitment StatusEnrolling By Invitation
If you need help finding a study or have any questions, please contact us at email@example.com or by phone at (888) 264-0005.